Measurement of Platelet Aggregation in Diabetics using the New Electronic Platelet Aggregometer

Jones, Rob; Delamothe, A.P.; Curtis, L. D.; Machin, S. J.; Betteridge, D. J.

doi:10.1111/j.1464-5491.1985.tb00610.x

Cited by 18 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B-TG [3,17], PF-4 [3,18] and TXA2 [19,20]). Even in young diabetics with no obvious vascular complications, platelet hyperaggregability has been demonstrated using more sensitive techniques such as whole blood impedance aggregation [21] or the measurement of platelet lifespan [3,22]. Thus, it is possible that the low 5-HT content of platelets in these two conditions is the result of a combination of decreased uptake and increased release.…”

Section: Discussionmentioning

confidence: 99%

Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease

Barradas

Gill

Fonseca

et al. 1988

Eur J Clin Investigation

139

View full text Add to dashboard Cite

Abstract. Intraplatelet serotonin (5-HT) content was determined in 23 patients with type I (insulin-dependent) diabetes mellitus (IDDM), 23 patients with type I1(non-insulin-dependent) diabetes mellitus (NIDDM), 29 patients with peripheral vascular disease (PVD) and 34 age-matched normal subjects. Intraplatelet 5-HT content in normal subjects showed an age-related decline (r = -0.45; P < 0.008), as has been previously demonstrated. The median 5-HT content in platelets of the young normal subjects was 4.36 (range: 3.62-6.79) nmol platelets, while that in the elderly normal subjects was 3.87 (range: 2.8-6.0) nmol lop9 platelets and that in young+elderly subjects was 4.05 (range: 2.8-6.8) nmol platelets. The median intraplatelet 5-HT content was significantly lower (P<0.002) in IDDM patients: 3-0 (range 1.3-6.3), NIDDM patients: 2.5 (range 1.7-5.8), PVD patients: 2.42 (range 0.94-4.98) nmol lop9 platelets than that in all young+elderly healthy subjects. The presence of hypertension in DM patients caused a small but significant (P < 0.05) decrease in intraplatelet 5-HT content, whilst its presence had no effect in PVD patients. In a smaller study, it was established that NIDDM and PVD patients have significantly (P < 0.002) greater plasma 5-HT concentrations than controls. Insulin-dependent diabetes mellitus patients had greater plasma 5-HT concentrations but this did not achieve statistical significance despite a 66% increment in its value. We conclude that the diminished 5-HT content in platelets and the increased plasma levels may reflect enhanced release of 5-HT by hyperactive platelets. This increase in plasma 5-HT may contribute to the pathogenesis of atherosclerosis and vasospasm.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease

Barradas

Gill

Fonseca

et al. 1988

Eur J Clin Investigation

139

View full text Add to dashboard Cite

show abstract

“…WBA-based hyperaggregability has been associated with adult respiratory distress syndrome, diabetes, and paraproteinemias. [90][91][92][93] In all instances of hyperaggregability, antiplatelet therapy, mostly aspirin, is effective, though it may be valuable to monitor therapy long-term with periodic aggregation, secretion, or UDHT assays. In MPD and MDS, lumiaggregometry may detect both hyperaggregability and storage pool deficiency and thus may predict either thrombophilia or bleeding.…”

Section: Hyperaggregabilitymentioning

confidence: 99%

Whole Blood Platelet Aggregometry and Platelet Function Testing

McGlasson

Fritsma

2009

Semin Thromb Hemost

117

View full text Add to dashboard Cite

Platelet aggregometry has been the reference method employed to detect, diagnose, and monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and impedance-based whole blood lumiaggregometry have advantages over light transmittance aggregometry in that they provide for enhanced specimen management and increase the test sensitivity to impairment of platelet granule secretion. Whole blood lumiaggregometry detects and identifies congenital and acquired platelet plasma membrane receptor defects, metabolic pathway secretion disorders, and storage pool deficiency. Whole blood lumiaggregometry is also being applied to antiplatelet therapy monitoring and identifies aspirin and thienopyridine resistance. There is growing interest in using impedance-based whole blood lumiaggregometry for near-patient whole blood platelet analysis and antiplatelet therapy monitoring. This article will also discuss other whole blood testing processes for assessing platelet function, particularly as applied to assessing the effect of antiplatelet medication.

show abstract

“…However, it seems likely that TXA2 plays an important role since the metabolite of TXA2 is increased in diabetic plasma [1][2][3] or urine [9], and also, platelet aggregation is known to be elevated in diabetics [3][4][5][6]. However, direct evidence of the participation of TXAi has been lacking.…”

Section: Discussionmentioning

confidence: 99%

“…These changes are thought to cause a tendency towards intravascular thrombosis [7] or vasoconstriction [7,8], leading to microangiop athy, including nephropathy [1][2][3][4][5][6]. On the other hand, increased renal production of TXB2 has been reported in several models of renal damage [9][10][11][12][13][14][15][16] and in patients with various kinds of diseases [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

“…Diabetes mellitus has been characterized by an in crease in the plasma level of thromboxane (TX) B2 [1][2][3], the stable derivative of TXA2, with an enhanced platelet aggregation [3][4][5][6]. These changes are thought to cause a tendency towards intravascular thrombosis [7] or vasoconstriction [7,8], leading to microangiop athy, including nephropathy [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of a Selective Thromboxane Synthetase Inhibitor OKY-046 on Experimental Diabetic Nephropathy

Hora

Oguchi²,

Furukawa³

et al. 1990

Nephron

View full text Add to dashboard Cite

To examine the effects of endogenous thromboxane A₂ on the development of diabetic nephropathy, we administered OKY-046, an inhibitor of thromboxane synthesis, to streptozotocin-induced diabetic rats. Animals were divided into three groups; nondiabetic control, diabetic, and diabetic with OKY-046, and were sacrificed 16 weeks after experimental procedures. The chronic oral administration of OKY-046 to diabetic rats significantly decreased plasma and urinary thromboxane B₂ levels. Urinary protein excretion and serum glucose levels were significantly lower in the OKY-046-treated diabetic rats than in the untreated diabetics (60.8 ± 23.2 vs. 94.1 ± 33.4 mg/day in the 16th week, p < 0.05 and 424.4 ± 93.3 vs. 614.4 ± 102.3 mg/dl in the 16th week, p < 0.01, respectively). Platelet aggregation was inhibited by OKY-046. Blood urea nitrogen was unaffected. Ultrastructural examination revealed that the thickness of glomerular basement membrane was markedly thinner in the OKY-046-treated diabetic rats than in the untreated diabetics (197.4 ± 29.6 vs. 288.6 ± 46.9 nm, p < 0.01). These results suggest that thromboxane A₂ may play an important role in the development and progression of diabetic nephropathy in rats.

show abstract

Measurement of Platelet Aggregation in Diabetics using the New Electronic Platelet Aggregometer

Cited by 18 publications

References 14 publications

Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease

Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease

Whole Blood Platelet Aggregometry and Platelet Function Testing

Effects of a Selective Thromboxane Synthetase Inhibitor OKY-046 on Experimental Diabetic Nephropathy

Contact Info

Product

Resources

About